From the Yahoo boardI believe the second site at St. George Hospital in London was to keep the study on time. This study is independent from the BOD or Oncy researchers. It makes since to keep it on schedule for Marsden's scheduled list of studies. Hopefully we shall hear some news in 22 days. This study is different fron the Glio trials, it has a beginning date and ending date in a facilty that has new trials waiting in the wings. With the large short position closing, it seems to point to a positive NR.
I am siding with the bolting shorts on this one.
Title: A phase 1 study to evaluate the feasibility, safety and biological effects of administering a wild-type reovirus (REOLYSIN), that selectively replicates in cells expressing activated Ras, intravenously to patients with advanced malignancies.
Principal research question: To identify the maximum tolerated dose (MTD) and describe the safety profile of Reolysin.
Methodology description: Dose finding (Phase 1/ 2)
Sample group description: Total number of RMH patients 40
Outcome measure description: The development of an innovative therapy for the treatment of solid tumours, iwhich can be taken forward in to further phase II and phase III trials.
Project web site: https://www.royalmarsden.org/
Research results: Research results are not currently collected by the NRR
Project organisation
This record refers to a single-centre study
Start date: 11 February 2004
End date: 1 February 2005
Project status: Ongoing
Contact person: Dr Johann De Bono
Section of Medicine
Royal Marsden NHS Trust
15, Cotswold Road
Sutton
Surrey
SM2 5NG
England
Telephone: 020 8643 8901
Fax: 020 7808 2048
E-mail: johann.de-bono@icr.ac.uk